
BIOEMTECH’s mission and passion is accelerating preclinical research of promising drugs, towards clinical translation, through precisely targeted services and products. BIOEMTECH leverages its own boutique laboratories to drive innovation and ensure quality, for evaluating new compounds in all stages of preclinical testing, GLP toxicology and alpha emitters therapy schemes. It has developed the eyesTM desktop cameras for real-time in vivo imaging of SPECT and PET radionuclides and dyes. The eyesTM offer unmatched excellence in the challenging in vivo imaging of alpha emitters (212Pb & 225Ac)…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.